IFPMA Joint Guideline on Publication of Clinical Trial Results (2017.10.30)
The IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) Joint Guideline on Publication of Clinical Trial Results in Medical Journals was approved by IFPMA and entered into force on June 10, 2010. The Japan Pharmaceutical Manufacturers Association (JPMA), the European Federation of Pharmaceutical Manufacturers and Associations (EFPIA), and the Pharmaceutical Research and Manufacturers of America (PhRMA), as well as their member companies, have committed in this guideline to submit at least the results of all company-sponsored Phase III clinical trials and other studies deemed to be of medical importance for publication in peer-reviewed medical journals. The new joint guideline is intended to ensure that the results are published in peer-reviewed medical journals. This new joint guideline requires submission of all trial results within its scope, regardless of whether the results are good or bad.
This IFPMA Joint Guideline was approved by the JPMA as well as EFPIA and PhRMA prior to IFPMA approval.
This Joint Guideline underwent a minor revision on October 30, 2017.